Full-Time
Staff Engineer / Staff Designer
Innovation
Updated on 9/10/2026
Becton Dickinson
10,001+ employees
Global medical devices and diagnostics provider
No salary listed
Durham, NC, USA + 1 more
More locations: Covington, GA, USA
Remote
Minimum four days in the office per week is required for most roles.
Bachelor's, Master's
 Biology & Biotech (1) |
|---|
Get referred to Becton Dickinson
See people who can refer or advise you
- A bachelor's degree in Engineering, Industrial Design, Human Factors, or a related field is required.
- At least 7 years of experience in medical device development, healthcare innovation, or consumer product development is required.
- Demonstrated experience progressing concepts from early ideation through validation and down-selection is required.
- Experience applying structured innovation methods such as Biodesign, Design Thinking, Jobs to Be Done, or Design for Six Sigma is required.
- Hands-on experience with prototyping, user testing, and formative evaluation is required.
- Familiarity with regulatory, usability, and risk considerations for medical or health-adjacent products is required.
- The ability to move ambiguity into clarity through structured experimentation and learning is required.
- The ability to evaluate concepts and make evidence-based recommendations for investment or termination is required.
- The ability to balance user desirability, technical feasibility, and business viability is required.
- Strong communication skills across technical, clinical, design, and executive audiences are required.
- Systems-thinking capability regarding downstream development, regulatory, and commercialization outcomes is required.
- Empathy for patients, caregivers, and consumers, particularly in home and self-care contexts, is required.
- The ability to lead without authority and influence cross-functional teams through insight and credibility is required.
- Willingness to travel 10% domestically and internationally is required.
- Identify focus areas for critical innovation projects.
- Translate prioritized needs and value propositions into multiple concept directions, articulating user benefits, technical approach, and business rationale.
- Define target customers and users, including patients, caregivers, and clinicians, and ensure concepts address needs across care settings, including home use.
- Lead early physical, digital, and experiential concept prototyping to explore usability, feasibility, and differentiation.
- Partner with engineering, industrial design, human factors, and clinical stakeholders to assess technical readiness and identify critical development gaps.
- Evaluate the early intellectual-property landscape and contribute to invention disclosures and protection strategies.
- Document assumptions, uncertainties, and learning plans required to advance concepts out of Innovation.
- Refine value propositions and differentiation against competitive and alternative solutions using testing and stakeholder feedback.
- Drive concept down-selection using criteria including user desirability, technical feasibility, regulatory risk, and business attractiveness.
- Partner with technical teams to assess design space and critical functions.
- Contribute to early technology and system architecture decisions that support scalable product development.
- Ensure concepts exiting Innovation are clearly defined, evidence-backed, and development-ready.
- Integrate work across engineering, design, clinical, regulatory, quality, marketing, and commercial teams.
- Bridge consumer design principles with medical device development rigor while maintaining safety and compliance.
- Collaborate globally to incorporate regional insights and ensure concepts can scale across markets.
- Communicate concept rationale, trade-offs, and recommendations to senior leaders and governance forums.
- Use storytelling, visuals, and prototypes to drive understanding and alignment.
- Support innovation capability building by mentoring teams and contributing to concept-development best practices.
- Experience designing or developing products intended for home care, self-use, or consumer health environments is strongly preferred.
- A master's degree in Engineering, Industrial Design, Human-Centered Design, or an equivalent field is preferred.
- Familiarity with regulatory, usability, and risk considerations for medical or health-adjacent products is preferred.
BD is a global medical technology company serving hospitals, labs, and healthcare providers with products across BD Medical, Life Sciences, and Interventional. Its offerings include medication management and delivery devices, safe specimen collection and transport systems, and minimally invasive surgical instruments. Its products help safe medication administration, preserve specimen integrity for diagnostics, and enable less-invasive procedures, saving time and improving outcomes. BD differentiates itself with a broad end-to-end portfolio, global reach, and focus on quality, safety, and service to support care across regions; its goal is to improve patient outcomes, lower costs, and increase efficiency in care environments.
Company Size
10,001+
Company Stage
IPO
Headquarters
Franklin Lakes, New Jersey
Founded
1961
Get referred to Becton Dickinson
See people who can refer or advise you
Simplify's Take
What believers are saying
- BD’s August 6, 2026 quarter delivered $5.0 billion revenue and $3.23 adjusted EPS.
- Management raised 2026 guidance after foreign-exchange-neutral growth beat expectations in Q3.
- Phasix enrollment finished August 13, 2026, strengthening BD’s hernia-prevention expansion path.
What critics are saying
- FDA classified BD’s intraosseous recall Class I on August 17, 2026.
- The recall lists four deaths, 45 serious injuries, and 75 complaints through July 22, 2026.
- Bard mesh litigation still haunts BD; another quality failure could trigger enterprise-wide trust collapse.
What makes Becton Dickinson unique
- BD’s February 9, 2026 Waters spin-off left a pure-play medtech portfolio.
- BD’s Vystra pen platform anchors GLP-1 and biologic delivery partnerships like EMS Brazil.
- BD’s interventional and surgery franchises sell mission-critical devices into hospital emergency workflows.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Tuition Reimbursement
Growth & Insights and Company News
6 month growth
↑ 9%1 year growth
↑ 9%2 year growth
↑ 9%Becton, Dickinson and Company shares have gained 19.6% over the past year, slightly trailing the S&P 500's 20.4% rise. However, in 2026 year-to-date, the stock has outperformed with a 20.2% gain versus the index's 13.7% advance. The medical technology company, valued at $50.5 billion by market cap, manufactures medical supplies, devices, laboratory equipment, and diagnostic products. It has outpaced the iShares U.S. Medical Devices ETF, which declined 9.5% over the past year. BDX's shares rose 3.8% on 6 August after reporting third-quarter results. Adjusted earnings per share of $3.23 exceeded analyst expectations of $3.14, whilst revenue of $5 billion surpassed the $4.9 billion forecast. Among 16 analysts covering the stock, the consensus rating is "Moderate Buy", comprising seven "Strong Buy" ratings and nine "Holds".
BD has appointed Gary Sorsher as executive vice president and chief quality officer, effective 8 September. Sorsher brings over 30 years of experience in quality leadership at medical technology companies, most recently serving as chief quality officer at Edwards Lifesciences. The appointment follows the announcement that Jeffrey Silvestri, senior vice president and global head of quality, will retire in October after more than 25 years with BD. Silvestri joined the company in 1998 and has been instrumental in strengthening BD's quality foundation. Tom Polen, BD's chairman, CEO and president, emphasised that quality is central to earning trust with customers and patients. He expressed confidence in Sorsher's ability to advance quality excellence across the organisation.
BD fully enrolls trial of resorbable mesh for hernia prevention. BD called completing enrollment in the study "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Published Aug. 13, 2026 Dive brief: * BD said Wednesday it has completed enrollment in a clinical trial of resorbable mesh for preventing incisional hernias after open abdominal surgery. * Investigators enrolled 477 patients across 32 sites in the U.S. and Europe to compare the effect of BD's Phasix mesh and primary suture closure on the rate of incisional hernias. * BD will follow patients through the trial's primary endpoint at 24 months, beyond which it expects to use the data to seek Food and Drug Administration authorization for the indication. Dive insight: Incisional hernia is a serious and relatively common postoperative complication of elective abdominal surgeries where a large incision is made through the abdominal wall. BD's Phasix is a resorbable mesh. CR Bard, which BD bought for $24 billion in 2017, received FDA clearance in 2015 for Phasix in settings including hernia repair. Later, long-term data on the device confirmed the absence of mesh complications such as pain and infection. BD has faced lawsuits over adverse events allegedly linked to Bard meshes made from other materials. By completing enrollment in its PREVENT trial, BD took a step toward expanding the Phasix label to cover the prophylactic use of the device in patients undergoing elective open midline laparotomy surgery. Evaluating Phasix in hernia prevention builds on "decades of innovation in abdominal wall surgery" and will generate evidence that could "help broaden the role of regenerative technologies for patients at risk of post-surgical complications," Rian Seger, worldwide president of surgery at BD, said in a statement. BD called completion of enrollment in the clinical trial "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Last week, the company reported double-digit growth in sales of its infection prevention and advanced tissue regeneration products in the third quarter of its financial year. Discussing tissue regeneration on BD's third-quarter earnings call, CEO Thomas Polen said the company expects "strong growth going forward." Polen supported the expectations by highlighting clinical trials that the company is running to bring its biomaterial "into new indications to continue to expand our presence in those spaces."
Becton Dickinson reported third-quarter fiscal 2026 sales of $4,983 million, whilst net income fell to $377 million. The medical technology company modestly raised its full-year outlook for low single-digit revenue growth. BD highlighted momentum in biologic drug delivery and GLP-1 partnerships, including a new semaglutide pen collaboration with EMS in Brazil. The company's Vystra Injection Pen platform is gaining traction in chronic disease treatment. FX-neutral revenue grew faster than expected, leading management to nudge guidance higher. However, the sharp drop in year-to-date net income and recent one-off loss raise questions about earnings quality. The company maintained its $4.20 annual dividend. Shares rose 6.8% following the results, though some analysts suggest the stock remains undervalued by approximately 25%.
BD reported third quarter fiscal 2026 revenue of $5.0 billion, up 5.4% as reported and 4.4% on a foreign exchange-neutral basis. GAAP diluted earnings per share from continuing operations reached $1.64, whilst adjusted diluted EPS came in at $3.23. Year-to-date cash from continuing operations increased 33.3% to $2.1 billion. Free cash flow rose 44.6% to $1.7 billion. The medical technology company updated its full-year guidance, expecting revenue growth towards the high end of its range whilst raising the midpoint of its adjusted diluted EPS guidance. The results represent BD's first full quarter following the 9 February 2026 spin-off of its Biosciences and Diagnostic Solutions business and its combination with Waters Corporation.